Investigational drug · Phase 2
YD0743
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Sepsis.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "YD0743"
First trial start
2026
Feb 2, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YD0743", any sponsor or status.
Conditions studied
As listed on its trial records.
- Sepsis
Largest trials
Live from ClinicalTrials.gov: studies naming "YD0743" as an intervention, largest first.
- Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDSPivotal-lookingRecruiting
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Industry
NCT07413094 · 309 participants (planned) · Start Feb 2, 2026 · Primary completion Dec 2026
Drug: YD0743; YD0743 Placebo · For: Sepsis
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Sepsis
- AZD4144Phase 21 trial
AstraZeneca · Sepsis, Acute Kidney Injury
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.